Since bypass RTK reactivation and/or tertiary <i>EGFR</i> mutations represent the majority of osimertinib-resistant cancers, these data suggest that targeting SOS2 has the potential to eliminate the majority of osimertinib resistance. Here, EGFR is linked to cancer.